



June 5, 2026

To whom it may concern:

Company Name: Innovacell Inc.
Representative: Representative Director Co-CEO
Colin Novick
Representative: Representative Director Co-CEO
Jason Sieger
(Code No.: 504A, Growth Market of the Tokyo Stock Exchange)
Point of Contact: Director CFO Yasushi Hosono
(<https://innovacell.com/contact/>)

**Announcement of Publication of English Translation of the “Logmi Finance Transcript”
for the Q1 FY2026 Progress Update video**

We hereby announce that the English translation of the “Logmi Finance Transcript” (Japanese version) of our Progress Update video for the first quarter of the fiscal year ending December 2026. The original Japanese article is a written transcript of the Q1 FY2026 Progress Update video (Japanese version) we released on May 20. We hope this English translation transcript will serve as a useful reference for gaining a deeper understanding of the progress of Innovacell Group’s business operations.

1. Release date : June 5, 2026
2. Logmi Finance URL : <https://finance.logmi.jp/en/articles/385121>
3. Distribution channels : FACTSET (FactSet Research Systems Inc.), LSEG (London Stock Exchange Group plc)

For your information, we separately released our Q1 FY2026 Progress Update video (English version) on May 20. The English translation of the “Logmi Finance Transcript” above is based on a transcript of the Japanese version video; it is not a transcript of the English version video available at the URL <https://innovacell.com/2529/?lang=en>.

■ **About Innovacell Inc. (<https://innovacell.com/>)**

The predecessor of Innovacell Inc. was a cell therapy start-up company spun out from the Medical University of Innsbruck (Austria). Innovacell Inc. was established in Japan in 2021 as the parent company of said Austrian company (currently Innovacell GmbH).

Innovacell group aims to improve patient health and QOL through the development and commercialization of cell therapies and regenerative medicine. It is currently focused on developing and commercializing regenerative medicine products for the treatment of urge and passive fecal incontinence as well as stress urinary incontinence.

ICEF15, the most advanced of the Group's pipeline products, aims to treat urge fecal incontinence by regenerating muscle tissue via the local administration of a patient's own skeletal myoblasts. ICEF15 is currently undergoing a multi-regional Phase III clinical trial in 11 European countries and Japan. To date, Innovacell GmbH has completed multiple clinical trials in Europe, including Phase IIb trials for ICEF15 (urge fecal incontinence) and ICES13 (stress urinary incontinence).

End